Expert Insights Benefit from guidance from board-certified specialists in internal and obesity medicine who prioritize your long-term health
Medical Eligibility Required Semaglutide and Tirzepatide cannot be prescribed to individuals with the following conditions: BMI under 27, eating disorders, Type 1 diabetes, gallbladder disease, substance abuse, recent bariatric surgery (within the past 6 months), pancreatitis or history of recurrent pancreatitis while taking a GLP-1 medication, medullary thyroid cancer, current pregnancy or breastfeeding, plans to become pregnant, diabetic retinopathy, multiple endocrine neoplasia type 2 (MEN2) or family history of MEN2, serious gastrointestinal disorders, or history of allergic reaction to Tirzepatide or Semaglutide
(See below!) Consensus report on safe use of GLP-1 medications in T1D Despite the fact that GLP-1 receptor agonists (and dual GLP-1/GIP receptor agonists) are not FDA-approved for use in T1D for any indication, people with T1D are still able to access these drugs since they are approved to treat obesity and overweight
This further amplifies the release of growth hormone (GH)
Structure and Mechanism of DHHC Protein Acyltransferases
